State of the Art Treatment - Hyponatremia, Heart Rate, et al
|
|
- Buck Porter
- 5 years ago
- Views:
Transcription
1 State of the Art Treatment - Hyponatremia, Heart Rate, et al Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu
2 Disclosure Research grant from Otsuka for the study: Tolvaptan in the treatment of volume overload in hyponatremic patients with heart failure (AQUA-AHF).
3 Prevalence of Hyponatremia in HF 50 w Hyponatremia (serum sodium < 135 meq/l) is common in patients hospitalized with HF 40 Patients (%) OPTIME ACTIV OPTIMIZE-HF ESCAPE EVEREST OPTIME-CHF-Klein L; Circulation. 2005; 111: ACTIV-Gheorghiade M, JAMA. 2004; 291 OPTIMIZE-HF- Gheorghiade M, Euro Heart J. 2007; 28: ESCAPE-Gheorghiade M, Arch Intern Med. 2007; 167 (18): EVEREST-Konstam M, JAMA. March 2007, 297 (12)
4 Arginine Vasopressin (AVP, ADH) Stimulation and Effects 1. Osmolality 2. Angiotensin II/NE 3. Arterial pressure/ cardiac volume + 1. Osmolality 2. Natriuretic peptides 3. Arterial pressure/ cardiac volume V1b-Ant pituitary Pancreas, Adrenal medula V 1a Receptor (VSMC, cardiomyocytes) AVP V 2 Receptors (collecting ducts) Vasoconstriction Myocardial stimulation Renal H 2 O reabsorption Verbalis JG. Cleve Clin J Med. 2006;73(suppl 3):S24-S33; Lee CR, et al. Am Heart J. 2003;146:9-18.
5 Hyponatremia Is Associated With Rehospitalization in HF Patients* % Na <135 meq/l Na 135 meq/l P<.0001 for all % Length of Stay, d In-Hospital Mortality, % *OPTIMIZE-HF registry data; N=48,612. Postdischarge Mortality, % Death or Rehospitalization Since Discharge, % Reprinted with permission from Gheorghiade M, et al. Eur Heart J. 2007;28:
6 PROGNOSTIC VALUE OF HYPONATREMIA VS. BNP PARK ET AL, JACC 2014;63:A786
7 J Cardiac Fail 2012;18:74 1 Duke data base :1,045 patients with heart failure due to systolic dysfunction, undergoing cardiac catheterization between 2000 and 2008
8 Hyponatremia and Long Term Outcome in HF The Duke Data Base Betari L et al J Cardiac Fail 2012;18:74 10%
9 Hyponatremia and Long Term Outcome in HF The Duke Data Base Betari L et al J Cardiac Fail 2012;18:74 Betari L et al J Cardiac Failure 2012:18:74
10 Relation of Serum Na Level to Long- Term Outcome After 1 st Hospitalization for HFPEF Rusinaru D et al Am J Cardiol 2009;103:405 Corrected vs. Persistent Hyponatremia
11 Hyponatremia in ADHF Treatment
12 Treatments for Hyponatremia In Patients With HF Improving hemodynamics. ACE inhibitors. Fluid restriction (poorly tolerated, only 1-2 meq/l per day). Diuresis (Hypertonic saline). Vasopressin receptor antagonists..
13 Nonpeptide AVP Receptor Antagonists Tolvaptan Lixivaptan Satavaptan Conivaptan Receptor V 2 V 2 V 2 V 1a /V 2 Route of administration Oral Oral Oral IV Urine volume Urine osmolality Na + excretion/ 24 h for low dose for high dose Company Otsuka CardioKine sanofiaventis Astellas Reprinted with permission from Verbalis JG, et al. Am J Med. 2007;120:S1-S21.
14 Change in Serum [Na + ] After 4 Days of Continuous IV Infusion of Conivaptan Placebo IV Conivaptan 40 mg/day IV Conivaptan 80 mg/day (n=29) (n=29) (n=26) 12 * LS Mean ± SE Change From Baseline [Na + ], meq/l * * * * * * Reprinted with permission from Zeltzer D, et al. Am J Nephrol. 2007;27: No Myelinolysis Time, day *P<.001, P=.034 vs placebo.
15 CV Mortality or HF Hospitalization Proportion Without Event Peto-Peto Wilcoxon Test: P=0.55 HR 1.04; 95%CI ( ) TLV 30 mg PLACEBO TLV PLC Months In Study
16 Adjudicated CV Mortality/Morbidity EVEREST Trial: Patients with HF and Hyponatremia Subjects with Baseline Sodium 130 meq/l (ITT Population) Tolvaptan Placebo Subjects with Baseline Sodium <130 meq/l (ITT Population) Proportion Remaining in Study Hazard Ratio: % CI Limits: 0.973,1.165) PLC TLV PLC TLV (p<0.05) Hazard Ratio: % CI Limits: 0.372, Months in Study Months in Study Overall CV Mortality/Morbidity (ITT) HR 1.04; 95%CI ( ) ATA on File: Protocols and
17 Efficacy and Safety of Tolvaptan in Patients Hospitalized With AHF The TACTICS-HF Study 257 patients with AHF within 24 hours presentation regardless of EF randomized either to tolvaptan 30 mg or placebo given at 0, 24 and 48 hours
18 Efficacy and Safety of Tolvaptan in Patients Hospitalized With AHF The TACTICS-HF Study 257 patients with AHF within 24 hours presentation regardless of EF randomized either to tolvaptan 30 mg or placebo given at 0, 24 and 48 hours
19 Short Term Effects of tolvaptan in Patients with AHF and Volume Overload- SECRET of CHF Study 250 patients with AHF Mean EF 34% 32% > 45% Randomized within 36 h sfter hospitalization to Tolvaptan30 mg/d or placebo for 7 days Konstam MA et al JACC 2017;69:
20 Short Term Effects of tolvaptan in Patients with AHF and Volume Overload- SECRET of CHF Study Konstam MA et al JACC 2017;69:
21 Short Term Effects of tolvaptan in Patients with AHF and Volume Overload- SECRET of CHF Study Konstam MA et al JACC 2017;69:
22 EVEREST: Furosemide Use Change4in4furosemide4use4(mg/day) Discharge Week41 Week !10!20!30!40 P=0.028!50!60 P=0.019 P=0.002 Follow!up Visit4* Placebo Tolvaptan *7 days post-treatment discontinuation
23 Tolvaptan in Acute Heart Failure- Time to Move On There is a disconnect between weight/fluid loss and dyspnea. It may be time to abandon the dyspnea endpoint in acute heart failure trials. Starling & Young JACC 2017:69;1407-8
24 2013 Guidelines For The Management of Heart Failure
25 Common. Hyponatremia and ADHF Summary Very strong biomarker for prognosis. Vasopressin receptor antagonists are the most effective treatment for correction of hyponatremia and volume overload. The drugs however, have not been shown to improve symptoms or prognosis in patients with both acute and chronic HF
26 HR at Discharge and Mortality / hospitalizations Lasky WK et al J Am Heart Assoc 2015;4;e ,217 medicare patients in Get with the guidelines HF
27 Relation Between Magnitude of HR Reduction and Change in LVEF in BB Trials. 35 trials ~23,000 patients Flannery et al AJC 2008
28 Relation Between Magnitude of HR Reduction and Mortality in BB Trials
29 HR and Survival in 2039 Patients with HFrEF Cullington D et al JACC 2014;2:213 HR significantly associated with survival. Each increase in resting HR by 10 bpm associated with 13% increase in annual mortality (HR: 1.13, 95% CI: 1.03 to 1.24, p ). Patients with HR > 70 bpm had worse survival compared to a reference group of < 57 bpm. ( HR: 1.47; 95% CI: 1.03 to 2.13, p. 0.04).
30 Meta-Analysis: BB Dose, HR Reduction, and Death in Patients With Heart Failure McAlister FA et al Ann Int Med 2009;150:784 Every 5 beats/min reduction in HR = 18% reduction in the risk for death.
31 Is Target Dose More Important Than Target HR? Porapakkham P et al CV Therapeutics 2010:10;1755 Target dose Carvedilol 50 mg /d, Bisoprolol 10 mg/d, Metoprolol Succinate 190 mg/d Target HR 60 bpm
32 HR or BB Dose? Results From The HF ACTION Trial Fiuzat M et al JACC Heart Failure 2016;4:109
33 Beta Blockers, Heart Rate and Outcome There is a strong relation between HR, BB dose and mortality in HF. The effect of BB on outcome is related to the magnitude of HR reduction.
34 Achieving a Maximally Tolerated b-blocker Dose in Heart Failure Patients Is There Room for Improvement? Bhatt AS et al JACC 2017:69;2542
35 Achieving a Maximally Tolerated BB Dose in HF Patients: Is There Room for Improvement? Bhatt AS et al JACC 2017:69;2542 Administration after a meal Smaller doses TID
Uri Elkayam, MD. Professor of Medicine University of Southern California Keck School of Medicine
Mihai Gheorghiade, MD Memorial Lecture Use of Vasopressin Antagonists for the Management of Hyponatremia and Volume Overload Uri Elkayam, MD Professor of Medicine University of Southern California Keck
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationHyponatremia in Heart Failure: why it is important and what should we do about it?
Objectives Hyponatremia in Heart Failure: why it is important and what should we do about it? Pathophysiology of sodium and water retention in heart failure Hyponatremia in heart failure (mechanism and
More informationNatriuretic Peptide Guided Therapy for Heart Failure
Natriuretic Peptide Guided Therapy for Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Duke Clinical Research Institute Disclosures Research Grants
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationDiastolic Heart Failure Uri Elkayam, MD
Diastolic Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Diastolic Heart Failure Clinical Definition A
More informationArginine vasopressin has attracted attention as a potentially
New Drugs and Technologies Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia John J. Finley IV, MD; Marvin A. Konstam, MD; James E. Udelson, MD Arginine vasopressin has
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More informationNeurohypophysis. AVP Receptors. Hyponatremia in Pituitary Disorders 9/29/2016. Lewis S. Blevins, Jr., M.D.
in Pituitary Disorders Lewis S. Blevins, Jr., M.D. Neurohypophysis AVP secreting neurons in SON and PVN Osmo- and thirst receptors/centers in anterior hypothalamus Ascending pathways from ANS and brainstem
More informationAccepted Manuscript. Tolvaptan in Acute Heart Failure: Time to Move On. Randall C. Starling, MD MPH, James B. Young, MD
Accepted Manuscript Tolvaptan in Acute Heart Failure: Time to Move On Randall C. Starling, MD MPH, James B. Young, MD PII: S0735-1097(16)35324-4 DOI: 10.1016/j.jacc.2016.09.005 Reference: JAC 22962 To
More information12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker
12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Heart Rate as a Cardiovascular Biomarker Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine,
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationTỐI ƯU HOÁ ĐIỀU TRỊ SUY TIM MẠN PGS. TS. CHÂU NGỌC HOA ĐHYD TPHCM
TỐI ƯU HOÁ ĐIỀU TRỊ SUY TIM MẠN PGS. TS. CHÂU NGỌC HOA ĐHYD TPHCM Signed by HFA / ESC/ HFSA/ ACC/ AHA Downloaded from http://circ.ahajournals.org/ at Amgen, Inc-- on May 20, 2016 3 In the year 2016, by
More informationAcute heart Failure. Critical cardiac care: update Markku S. Nieminen Helsinki, Finland. M S Nieminen, AHF ,ESC Stockholm
Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen Helsinki, Finland M S Nieminen, AHF 300810,ESC Stockholm Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationThe Art and Science of Diuretic therapy
The Art and Science of Diuretic therapy Dr. Fayez EL Shaer Associate Professour of cardiology Consultant cardiologist MD, MSc, PhD, CBNC, NBE FESC, ACCP, FASNC,HFA KKUH, KFCC Heart failure: fluid overload
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationHow to define the target population?
Heart Failure 2011 22-24 May. Gothenburg, Sweden Mortality or morbidity as target in acute heart failure trials How to define the target population? Marco Metra, Brescia The Burden of Acute HF Acute HF
More information9/24/2010 S U ts n ) s tie a 4.7 illio (m 3.5 ilu rt F a Outpatient e H Inpatient * 50 s 60 s 70 s >80
Exciting Times: Advances in Heart Failure Dana McGlothlin, MD Associate Professor of Medicine Advanced Heart Failure and Transplant Program Medical Director, CCU Overview HF Statistics Therapies for chronic
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationFrom Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs. Florence Wong University of Toronto. Falk Symposium October 14, 2007
From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs Florence Wong University of Toronto Falk Symposium October 14, 2007 Sodium Retention in Cirrhosis Occurs as a result of hemodynamic
More informationAldosterone Antagonist. Hyd/ISDN*
Μedical management of heart failure: Update 2014 Dr John T Parissis Attikon University Hospital Athens, Greece Disclosures: Received honoraria as consultant or research grants by Orion- Pharma, Servier,
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationΟξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;
Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Γ. Φιλιππάτος, MD, FACC, FESC, FCCP Επ. Καθηγητής Καρδιολογίας Πανεπ. Αθηνών Clinical Outcomes in Patients
More informationMonitoring of Renal Function in Heart Failure
Monitoring of Renal Function in Heart Failure Adriaan A. Voors, cardiologist The Netherlands Disclosures AAV received consultancy fees and/or research grants from: Alere, Bayer, Cardio3Biosciences, Celladon,
More informationComparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience
ORIGINAL ARTICLE Korean J Intern Med 2018;33:561-567 Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience Gun Ha Park 1,2, Chang Min
More informationCardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationCase Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationTolvaptan (Samsca) for Hyponatremia: Is It Worth Its Salt?
Tolvaptan (Samsca) for Hyponatremia: Is It Worth Its Salt? Timothy Reilly, PharmD, BCPS, and Benjamin Chavez, PharmD, BCPP INTRODUCTION Hyponatremia is the most common electrolyte abnormality in patients
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationArginine vasopressin (AVP) is a
Akash Parashar, MD; Patrick Martinucci, DO; Mandip Panesar, MD The authors are with the University at Buffalo, Erie County Medical Center, Buffalo, New York. Dr. Panesar is a member of D&T s Editorial
More informationBiomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following
More informationSliwa et al. JACC 2004;44:
TREATMENT OF ADVANCED HEART FAILURE HEART DISEASE IN KENTUCKY Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationUsing Lung Ultrasound to Diagnose and Manage Acute Heart Failure
Using Lung Ultrasound to Diagnose and Manage Acute Heart Failure Jennifer Martindale, MD Assistant Professor Department of Emergency Medicine SUNY Downstate/Kings County Hospital Brooklyn, NY What is acute
More information11/4/2010. Learning Objectives. Question 1. Question 2 PLEASE ANSWER THE HYPONATREMIA PRE-ACTIVITY TEST QUESTIONS. A. True B.
Faculty Disclosures James S. Kalus, PharmD, BCPS (AQ CV) Senior Manager, Patient Care Services Henry Ford Hospital, Detroit, MI NO RELATIONSHIPS TO DISCLOSE Saturday, October 23, 2010 Hemant Dhingra, MD
More informationARGININE VASOPRESSIN (AVP)
ARGININE VASOPRESSIN (AVP) AFFECTS BLOOD PRESSURE AND RENAL WATER REABSORPTION WHAT ELSE DOES IT DO? Michael F. Michelis, M.D., F.A.C.P., F.A.S.N. Director, Division of Nephrology Lenox Hill Hospital,
More informationBiomarker-guided HF: What have we learned (so far)?
Biomarker-guided HF: What have we learned (so far)? James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Director, Cardiac ICU Massachusetts General Hospital DECLARATION
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationPractical Points in Cardiorenal Syndrome
Practical Points in Cardiorenal Syndrome Vichai Senthong, MD. Cardiovascular Unit, Faculty of Medicine Khon Kaen university HFCT Annual Scientific Meeting June 16, 2017, Eastin Grand Sathorn Hotel, Bangkok
More informationTOLVAPTAN: A NEW APPROACH TO THE MANAGEMENT OF EU- VOLEMIC AND HYPERVOLEMIC HYPONATREMIA
Volume 22, Issue 10 July 2007 TOLVAPTAN: A NEW APPROACH TO THE MANAGEMENT OF EU- VOLEMIC AND HYPERVOLEMIC HYPONATREMIA Olamide Oshikoya, Pharm. D Candidate Hyponatremia is the most common electrolyte disorder
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationBeta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center
Beta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center Beta-blockers: What s known 30 Years 30 Careers Physician clarity regarding
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationManagement of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU
Management of acute decompensated heart failure and cardiogenic shock Arintaya Phrommintikul Department of Medicine CMU Acute heart failure: spectrum Case 64 y/o M with Hx of non-ischemic DCM (LVEF=25-30%)
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationTERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018
TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 Carlo Lombardi Cattedra di Cardiologia Università e Spedali Civili di Brescia All-cause mortality in the European
More informationTips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance
Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance J. Parissis Attikon University Hospital, Athens, Greece Disclosures ALARM investigator received
More informationΟξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες
Οξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες Στράτος Θεοφιλογιαννάκος, MD, PhD Ιατρείο Καρδιακής Ανεπάρκειας, Γ Πανεπιστημιακή Καρδιολογική Κλινική ΑΠΘ, ΠΓΝ Ιπποκράτειο
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationHeart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital
Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital Disclosures Chair or Committee Member of trials or registries sponsored by Novartis, Bayer, Cardiorentis, Servier
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationA Study To Evaluate The Efficacy Of Tolvaptan In Correction Of Hyponatremia And Its Effect On..
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 5 Ver. 11 (May. 2018), PP 29-34 www.iosrjournals.org A Study To Evaluate The Efficacy Of Tolvaptan
More informationHeart failure (HF) is a clinical syndrome with enormous relevance given its constantly. Benefits of early treatment with
A low percentage of patients achieve optimal β-blocker doses and optimal heart rate values with β-blocker administration. Ivabradine has been recognized not only for providing a prognostic benefit, but
More informationV2 Receptor Antagonist; Tolvaptan
Review ISSN 1738-5997 (Print) ISSN 2092-9935 (Online) Electrolyte Blood Press 9:50-54, 2011 http://dx.doi.org/10.5049/ebp.2011.9.2.50 V2 Receptor Antagonist; Tolvaptan Joo-Hark Yi, M.D. Hyun-Jong Shin,
More informationHow might biomarkers and other strategies help establish adequacy of care?
How might biomarkers and other strategies help establish adequacy of care? James L. Januzzi, Jr, MD, FACC, FESC Hutter Family Professor of Medicine, Harvard Medical School Cardiology Division, Massachusetts
More informationRisk Stratification in Heart Failure: The Role of Emerging Biomarkers
Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationHyponatremia 11/4/2010. Learning Objectives
JAMES S. KALUS, PHARM.D, BCPS (AQ-CARDIOLOGY) Senior Manager, Patient Care Services, Department of Pharmacy Services Henry Ford Hospital, Detroit, MI NO RELATIONSHIPS TO DISCLOSE ANGELA STEWART, PHARM.D,
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationMortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials
Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Christopher M. O Connor, MD Professor of Medicine Director, Duke Heart Center Acting Chief, Division of Cardiology
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationChristopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University Editor
New Strategies in the Management of Acute and Advanced Heart Failure Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University
More informationTHE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.
THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationBehandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion
Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More informationTherapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure
J Pharmacol Sci 124, 000 000 (2014) Journal of Pharmacological Sciences The Japanese Pharmacological Society Current Perspective Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure
More informationHeart Failure Medications: Who Needs What Drug Now? Disclosures
Heart Failure Medications: Who Needs What Drug Now? Simon Jackson MD FRCPC MMedEd Professor of Medicine (Cardiology) Dalhousie 1 Disclosures Honoraria and educational grants from: Actelion (medications
More informationTreatment with Hydralazine and Nitrates Uri Elkayam, MD
Treatment with Hydralazine and Nitrates Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Hydralazine and Isosorbide Dinitrate
More informationDIURETICS-4 Dr. Shariq Syed
DIURETICS-4 Dr. Shariq Syed AIKTC - Knowledge Resources & Relay Center 1 Pop Quiz!! Loop diuretics act on which transporter PKCC NKCC2 AIKTCC I Don t know AIKTC - Knowledge Resources & Relay Center 2 Pop
More informationEffect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial
Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial Aldo P. Maggioni, MD, FESC Associazione Nazionale Medici
More information